Immunotherapy, Inflammation and Colorectal Cancer is a research paper published in Cells (2020). On theSindex it has a DataRank of 0. It has been cited 302 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P01 CA128814
NIAAA NIH HHS
Grant: P50 AA011999
NIAAA NIH HHS
Grant: U01 AA027681
NIAID NIH HHS
Grant: R01 AI043477
NCI NIH HHS
Grant: R01 CA211794
National Institutes of Health
Grant: 1U01AA027681-01
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
National Institutes of Health
Grant: 5R01AI043477-10
Regulation of NF-kB and IKK by proinflammatory stimuli
National Institutes of Health
Grant: 3P50AA011999-12S1
Southern California Research Center for ALPD and Cirrhosis
National Institutes of Health
Grant: 5P01CA128814-08
ER Stress and Mitochondrial Biogenesis in Melanoma
National Institutes of Health
Grant: 5R01CA211794-03
Role of p62/SQSTM1 in obesity-induced liver cancer
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 2 of Multi-omics analyses of human colorectal cancer revealed three mitochondrial genes potentially associated with poor outcomes of patients
Additional file 2 of Multi-omics analyses of human colorectal cancer revealed three mitochondrial genes potentially associated with poor outcomes of patients
Additional file 1 of Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Additional file 1 of Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Additional file 1 of TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
Additional file 1 of TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
Additional file 5 of Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy
Additional file 5 of Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy
Additional file 1 of Prognostic and tumor immunity implication of inflammatory bowel disease-associated genes in colorectal cancer
Additional file 1 of Prognostic and tumor immunity implication of inflammatory bowel disease-associated genes in colorectal cancer
Additional file 1 of Preoperative prediction of microsatellite instability status in colorectal cancer based on a multiphasic enhanced CT radiomics nomogram model
Additional file 1 of Preoperative prediction of microsatellite instability status in colorectal cancer based on a multiphasic enhanced CT radiomics nomogram model
Additional file 2 of Preoperative prediction of microsatellite instability status in colorectal cancer based on a multiphasic enhanced CT radiomics nomogram model
Additional file 2 of Preoperative prediction of microsatellite instability status in colorectal cancer based on a multiphasic enhanced CT radiomics nomogram model
Additional file 2 of ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization
Additional file 2 of ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization
Additional file 3 of ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization
Additional file 3 of ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization
Additional file 6 of ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization
Additional file 6 of ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization